Edition:
India

Fulcrum Therapeutics Inc (FULC.OQ)

FULC.OQ on NASDAQ Stock Exchange Global Market

13.53USD
2:29am IST
Change (% chg)

$0.62 (+4.80%)
Prev Close
$12.91
Open
$13.18
Day's High
$13.60
Day's Low
$13.18
Volume
3,742
Avg. Vol
15,762
52-wk High
$15.79
52-wk Low
$4.37

Latest Key Developments (Source: Significant Developments)

Fulcrum Therapeutics Announced Results Of Phase 1 Clinical Trial Of Losmapimod In FSHD
Friday, 4 Oct 2019 

Oct 4 (Reuters) - Fulcrum Therapeutics Inc ::FULCRUM THERAPEUTICS ANNOUNCED RESULTS OF PHASE 1 CLINICAL TRIAL OF LOSMAPIMOD IN FSHD.FULCRUM THERAPEUTICS-PRELIMINARY RESULTS FROM PHASE 1 CLINICAL TRIAL OF LOSMAPIMOD IN PATIENTS WITH FSHD INDICATE LOSMAPIMOD WAS GENERALLY WELL TOLERATED.FULCRUM THERAPEUTICS- PRIMARY OBJECTIVE OF TRIAL WAS TO INVESTIGATE SAFETY AND TOLERABILITY OF LOSMAPIMOD IN HEALTHY VOLUNTEERS AND IN FSHD PATIENTS.FULCRUM THERAPEUTICS- LOSMAPIMOD WAS WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS (SAES) REPORTED.  Full Article

Fulcrum Therapeutics Quarterly Loss Per Share $9.21
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Fulcrum Therapeutics Inc ::FULCRUM THERAPEUTICS INC QUARTERLY LOSS PER SHARE $9.21.FULCRUM THERAPEUTICS INC SAYS AS OF JUNE 30, 2019, CASH AND CASH EQUIVALENTS WERE $49.6 MILLION, AS COMPARED TO $72.8 MILLION AS OF DECEMBER 31, 2018.FULCRUM THERAPEUTICS - EXPECTS EXISTING CASH AND CASH EQUIVALENTS, WILL BE SUFFICIENT TO ENABLE TO FUND OPERATING EXPENSES, CAPITAL EXPENDITURE REQUIREMENTS INTO Q3 OF 2021.  Full Article

Foresite Capital Fund IV, L.P. Reports 7.2% Passive Stake In Fulcrum Therapeutics As Of July 22
Monday, 29 Jul 2019 

July 29 (Reuters) - Fulcrum Therapeutics Inc ::FORESITE CAPITAL FUND IV, L.P. REPORTS 7.2% PASSIVE STAKE IN FULCRUM THERAPEUTICS AS OF JULY 22 - SEC FILING.  Full Article

Fulcrum Therapeutics Shares Open 9.4% Below IPO Price in Debut
Thursday, 18 Jul 2019 

July 18 (Reuters) - Fulcrum Therapeutics Inc ::FULCRUM THERAPEUTICS SHARES OPEN AT $14.50 IN DEBUT ON THE NASDAQ VERSUS IPO PRICE OF $16.00/SHARE.  Full Article